Clinical Trial Update: Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating aripiprazole for psychosis associated with substance use has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorder
• Substance Use Disorder

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Northwell Health | Conditions: Substance Abuse, Substance Dependence | Phase 4 | Status: WITHDRAWN